Industry
Biotechnology
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Loading...
Open
15.45
Mkt cap
316M
Volume
469K
High
15.63
P/E Ratio
-3.68
52-wk high
74.49
Low
14.42
Div yield
N/A
52-wk low
14.42
Portfolio Pulse from
January 24, 2025 | 5:15 pm
Portfolio Pulse from
January 22, 2025 | 9:00 pm
Portfolio Pulse from
January 22, 2025 | 12:30 am
Portfolio Pulse from
January 17, 2025 | 1:15 am
Portfolio Pulse from
January 10, 2025 | 5:15 pm
Portfolio Pulse from
January 08, 2025 | 5:15 pm
Portfolio Pulse from
January 06, 2025 | 5:00 pm
Portfolio Pulse from
January 03, 2025 | 5:15 pm
Portfolio Pulse from
January 02, 2025 | 4:00 pm
Portfolio Pulse from
December 31, 2024 | 5:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.